List of medicines under additional monitoring

The list of medicines under additional monitoring includes medicines authorised in the European Union (EU) that are being monitored particularly closely by regulatory authorities. Medicines under additional monitoring have a black inverted triangle displayed in their package leaflet and summary of product characteristics, together with a short sentence explaining what the triangle means.

Updated on 28 January 2026:
'Summary of changes in January 2026' section

The list includes centrally and nationally authorised medicines (CAPs) in the following categories:

• medicines that contain a new active substance that was not contained in any authorised medicine in the EU on 1 January 2011;
• biological medicines authorised after 1 January 2011 - this applies to all biological medicines including biosimilars;
• medicines for which the marketing-authorisation holder is required to carry out a post-authorisation safety study (PASS);
• medicines given conditional approval or authorised under exceptional circumstances and medicines authorised with specific obligations on the recording or monitoring of suspected adverse drug reactions.

Summary of changes in January 2026

The following CAPs have been added to the list:

• Osqay – New biological
• WAYRILZ – New active substance
• Teizeild – New active substance and new biological
• Waskyra - New active substance, new biological and PASS
• VacPertagen – New active substance and new biological
• Inluriyo – New active substance
• Dawnzera – New active substance
• Ondibta – New biological
   

The following CAPs have been removed from the list:

• ABSIMKY – Withdrawal of marketing authorisation
• Copiktra – Withdrawal of marketing authorisation
• Evrysdi – Five years following its authorisation (April 2021)
• Ronapreve - Withdrawal of marketing authorisation
• Abevmy - Five years following its authorisation (May 2021)
• Kesimpta - Five years following its authorisation (April 2021)
• Drovelis - Five years following its authorisation (June 2021)
• Vazkepa - Five years following its authorisation (March 2021)
• Oyavas - Five years following its authorisation (April 2021)
• Alymsys - Five years following its authorisation (April 2021)
   

The following NAPs have been added to the list:

• Prufibry – New biological

The following NAPs have been removed from the list:

• Sublivac Birke - Five years following its authorisation (September 2018)
• Sublivac Bäume - Five years following its authorisation (September 2018)

List of medicines under additional monitoring

List of medicinal products under additional monitoring

Reference Number: EMA/245297/2013 Rev. 140

List of medicinal products under additional monitoring

Reference Number: EMA/245297/2013 Rev. 140

Annex V - List of hydroxyethyl starch (HES)-containing medicinal products in the European Union

Reference Number: EMA/48335/2014 corr. 7

Annex V - List of hydroxyethyl starch (HES)-containing medicinal products in the European Union

Reference Number: EMA/48335/2014 corr. 7

Annex XIII - List of Valproate and related substances in the European Union

Reference Number: EMA/11799/2015 Corr. 5

Annex XIII - List of Valproate and related substances in the European Union

Reference Number: EMA/11799/2015 Corr. 5

Annex XV - List of topiramate containing medicinal products in the European Union

Reference Number: EMA/227981/2024

Annex XV - List of topiramate containing medicinal products in the European Union

Reference Number: EMA/227981/2024

• European public assessment reports (EPARs) for medicines under additional monitoring
• Background information: Medicines under additional monitoring
• Product-information templates
• European Commission: The EU pharmacovigilance system